These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33904788)

  • 1. Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.
    Saavedra JM
    Physiology (Bethesda); 2021 May; 36(3):160-173. PubMed ID: 33904788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
    Mancia G
    Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications.
    Ning L; Rong J; Zhang Z; Xu Y
    Pharmacol Res; 2021 May; 167():105409. PubMed ID: 33465472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
    Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
    Tadic M; Cuspidi C
    J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
    Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J
    J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks.
    Okumura T; Murohara T
    Hypertens Res; 2024 Sep; 47(9):2598-2600. PubMed ID: 38951682
    [No Abstract]   [Full Text] [Related]  

  • 9. The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.
    Harky A; Chor CYT; Nixon H; Jeilani M
    J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320320987118. PubMed ID: 33412991
    [No Abstract]   [Full Text] [Related]  

  • 10. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
    Ferrara F; Vitiello A
    Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
    Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
    J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Expert Rev Cardiovasc Ther; 2021 Jan; 19(1):99-100. PubMed ID: 33112190
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
    Patel AB; Verma A
    JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 16. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.
    Latil M; Camelo S; Veillet S; Lafont R; Dilda PJ
    Drug Discov Today; 2021 May; 26(5):1311-1318. PubMed ID: 33609783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and inhibitors of the renin-angiotensin-aldosterone system.
    Hussain M; Jabeen Q; Ahmad FU; Kashif-Ur-Rehman ; Fatima M; Shaukat S; Majeed A; Barkat MQ; Wu X
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):815-816. PubMed ID: 33198546
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-Angiotensin System Modulation in Adults With COVID-19-Reply.
    Self WH; DeClercq J; Orr M;
    JAMA; 2023 Aug; 330(7):664-665. PubMed ID: 37581675
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
    Salvador GL; Marmentini VM; Cosmo WR; Junior EL
    Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.